Trends in Healthcare Investments and Exits 2018 - Mid-Year Report
1 like645 views
The mid-year 2018 report highlights strong growth in U.S. healthcare venture fundraising, reaching $4.5 billion, and anticipates surpassing the previous record of $9.1 billion from 2017. Investments in biopharma, particularly in series A and platform companies, are surging, while device investments show stability with a notable focus on non-invasive monitoring technologies. Biopharmaceutical IPO activity is also on track to exceed 2017's performance, with 30 IPOs already completed in the first half of 2018.
Trends in Healthcare Investments and Exits 2018 - Mid-Year Report
- 1. Trends in Healthcare Investments and Exits 2018 Innovation Wave Drives Robust Activity MID-YEAR REPORT 2018 Follow @SVB_Financial Engage #SVBHealthcare
- 2. Table of Contents Trends in Healthcare Investments and Exits Mid-Year 2018 2 Mid-Year 2018 Key Highlights 3 Healthcare Investments and Fundraising 5 SVB Deep Dive: Tools Driving Synthetic Biology in Life Science 18 Healthcare Exits and IPOs 20 Biopharma Unicorns: 2013 – 2018 21 Second Half of 2018 Outlook 29 Glossary 30 About the Authors 31
- 3. Mid-Year 2018 Highlights: Investments Pioneering Innovations, Drug Development Create Investor Excitement Trends in Healthcare Investments and Exits Mid-Year 2018 3 • Atmid-year, U.S. healthcareventurefundraising reached$4.5 billion,and is onpacetocloselymatch the2017recordof$9.1 billion. • Investmentsin VC-backedbiopharmacontinuedto surge,whiledeviceremainedstable.Dx/Tools investingdecreased. Full-year2018investmentin venturelifesciencecompanieslikelywillreacha newhigh,surpassingtherecord$17.3 billion investedin 2017. • BiopharmaSeriesA investmentsareexploding,and by mid-year reached$2.6 billion– comparedtothe full-yeartotalof$2.3 billionin 2017. • By indication, investorinterestis driving biopharma platformcompaniestolevelssimilar tooncology, and orphan/raredealsare makinga comeback. • Underscoringrobustpre-IPO biopharmavaluations, step-upsfromSeriesA toBhaveseen2xto3x increasesin thepast 18 months. • Non-invasivemonitoringand imagingcompaniesare drivinginvestmentsin SeriesA devicecompanies. • Whiledevicepre-moneyvaluationsalsohaveseen largestep-upsfromSeriesA toB, SeriesD valuations areflatordownrounds. • Investmentin Dx/Toolsoverallis laggingin 2018, dragged downby a largedropin DxTests deals. • On thebrightside, R&DToolssaw 20deals fromthe mostactiveinvestorsby mid-year, representing60% ofalldollarsinvestedin Dx/Toolsin 1H2018. • Investmentsin syntheticbiologybuildingblocks, includingcomputationaldesign,CRISPR editing, DNA/RNAsynthesisand organismengineeringtools, haveclimbedin 2017and 2018. • Thesecompaniesarerevolutionizingthefield ofsyntheticbiologywithhardwareand biochemical advancesin DNA/RNAsynthesis.
- 4. Mid-Year 2018 Highlights: Exits Biopharma IPOs Are Poised to Blow Past 2017 Numbers Trends in Healthcare Investments and Exits Mid-Year 2018 4 • 75 VC-backedbiopharmaunicornshavereached valuationsof$1 billionorhighersince2013– either throughacquisition orin thepublicmarkets.This year is shapinguptobeanotherstrongyear. These biopharmaexitsarecreatingthemomentumfor strongfundraisingand investment. • In 1H2018, 30biopharmacompanieswentpublic– comparedto31 IPOs forallof2017. • BiopharmaM&Ais slowing,as largerroundsand highervaluationsmakeearly-stageM&Aless appealing. • Instead, companieslookingtogopublicare replenishingthebiopharmaIPO queue.This is fueled by largepre-moneyIPO valuationsdrivenby continuedtopcrossoverinvestoractivity. • DeviceM&Ais stable,buttheIPO marketis favoring neuro-focusedcompanies,withthreeIPOs in 1H 2018. • PMA/DeNovopathwaycompaniescontinueto achievebetterM&Avalues,highermultiplesand fastertimestoexitthan510(k) companies. • However,overthelast twoyears, 510(k) device valuesand multipleshaveincreased. • Dx/ToolsM&Aactivity is increasing,butthesedeals havelowerupfrontvaluesand longertimesto exit. • Thereare manylater-stageDx/Toolscompaniesthat areshapingupas acquisition candidates, with25 still-privatecompaniesvaluedat $150 millionor higher.
- 5. 5 Healthcare Investments and Fundraising: Biopharma Advancements Drive Investor Activity Trends in Healthcare Investments and Exits Mid-Year 2018
- 6. Trends in Healthcare Investments and Exits Mid-Year 2018 6 U.S. HC Venture Fundraising Stays on Torrid Pace U.S. Healthcare Venture Fundraising*, 2009 – 2018 $5.2 $1.8 $3.7 $3.6 $3.9 $6.1 $7.5 $7.2 $9.1 $4.5 2009 2010 2011 2012 2013 2014 2015 2016 2017 1H 2018 Fundraisingisonpacetomatchthe2017 totalof$9.1B–countertoourearly2018 predictionthattheannualtotalwould decline.Aconfluenceofeventsisdriving investmentandfundraisingtonewlevels. Rapidtechnologicaladvances,leadingto clinicalbreakthroughs,arebenefiting patientsandinvestorsalike.Inthis environment,quickexitsareunderpinningan explosionof activity,particularlyin biopharma,attractingnewpoolsofcapital andgiantinvestmentsbytraditionalandnon- traditionalinvestors,includingtechinvestors. Withtheentryof artificialintelligence(AI) andmachinelearning(ML),thesetech investorsseehugeopportunitiesindrug developmentandthetoolsrequiredtohelp identifycuresfor arangeofdiseases. ThebiopharmaIPOwindowisrewarding investorswithquickvaluationstep-ups (manycompanieshadIPOswithintwoto threeyearsofSeriesA).Thispathtoliquidity istranslatingintorenewedexcitementby limitedpartnerswhoare eagertokeepthe investmentcyclegoingbysupportinglarger venturefundraisesatafasterpace. *SVB calculates only the dollars allocated to healthcare by U.S. venture funds orfunds investing primarily in the U.S. Source:PitchBook and SVB proprietary data. HC VC $ Fundraised ($ BILLIONS)
- 7. 36 18 14 16 5 32 19 12 12 9 19 17 11 6 3 Oncology Platform Orphan/Rare Disease Neuro Anti- Infective 2016 2017 1H 2018 2016* 2017* 1H 2018 # of Investments 122 128 77 Total Series A Funding ($M) $2,299 $2,259 $2,632 Corporate Investments (%) 26% 31% 16% Trends in Healthcare Investments and Exits Mid-Year 2018 7 Biopharma Series A Deals Set Blazing Pace U.S. Series A Biopharma Investments, 2016 – 1H 2018 $1,395M $987M $650M $281M $2,362M *2016 &2017 numbers amended based on PitchBook financing updates. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data. 2017 Median Series A Funding by Quarter ($M) 75th Quartile 25th Quartile 2018 Median Series A Funding by Quarter ($M) $19.1 $6.9 $5.9 $11.0 $- $10.0 $20.0 $30.0 $40.0 $50.0 $60.0 2017Q1 2017Q2 2017Q3 2017Q4 $8.0 $32.5 $- $10.0 $20.0 $30.0 $40.0 $50.0 $60.0 2018Q1 2018Q2 By mid-year, biopharma Series A investments reached $2.6B, already surpassing the full-year 2017 total. The activity was punctuated by a total of $1.8B invested in 15 big-money deals. Four deals each raised $250M+ (Allogene, Harmony, Viela and Cellularity), and an additional 11 deals each raised $50M+. Series A investment is on pace to reach 150 deals in 2018. Tech, angel and incubator/accelerator investors drove Q1 deal-making. Large venture healthcare syndicates (with corporates) led Q2 activity in fewer deals, driving up the Q2 2018 median deal value to more than $30M. Oncology Platform Orphan/ Rare Disease Neuro Anti- Infective Series A Deals Series A by Indication
- 8. Trends in Healthcare Investments and Exits Mid-Year 2018 8 Venture and Crossovers Lead Biopharma Activity Most Active New Investors* in Biopharma, 2017 – 1H 2018 *Most ActiveNew Investors in biopharma defined as Top 60 venture and corporate investors based on new investments in 2016–2017. Financing data through 6/15/18. Platform companies have technologies with multiple ornon specified indications. Source:PitchBook and SVB proprietary data. 26 20 17 15 13 12 11 10 9 8 7 New investors joining the most active list include 5AM, 6 Dimensions, HBM, Third Rock, Versant and crossovers RA Capital and Rock Springs. By indication, the most active investors in platform companies were Arch, Orbimed and Third Rock (4+ deals each), in oncology were 6 Dimensions, Celgene, GV, Orbimed, Osage, Versant and Vivo (4+ deals each) and in orphan/rare were 5AM, Orbimed and RA Capital (3+ deals each). # OF DEALS Corporate Investor
- 9. 44 30 18 13 9 5 8 7 3 3 3 3 5 2 4 1 1 6 1 2 Oncology Platform Orphan/Rare Disease Neuro Anti-Infective Auto-Immune Metabolic Early Stage Late Stage Undesignated Trends in Healthcare Investments and Exits Mid-Year 2018 9 Oncology and Platform Deals Capture Most Interest Most Active New Investments* in Biopharma by Indication, 2017 – 1H 2018 $2,486M $907M $2,276M $999M $639M $648M $286M Underscoring the recent influx of capital over the past two years from the most active investors, every top indication in 1H 2018 other than oncology has already surpassed investment levels for full-year 2016. Waves of new biopharma investment are pushing funding for platform companies to levels similar to oncology and driving a comeback for orphan/rare drugs. *Most ActiveNew Investments in biopharma defined as Top 60 venture and corporate investors based on new investments in 2016–2017. Platform companies have technologies with multiple ornon specified indications. Early Stage defined as Series A &B; LateStage defined as Series Cand later. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data. # DEALS | $ MILLIONS Platform Orphan/Rare Ophthalmology Auto-immune Trends:
- 10. Trends in Healthcare Investments and Exits Mid-Year 2018 10 Robust IPOs Lead to Soaring Private Valuations Series A/B Deals, Size and Valuation by Most Active Investors*, 2013 – 1H 2018 14.3 25.522.8 28.5 22.0 44.0 28.7 42.2 28.6 44.946.0 58.0 0.0 20.0 40.0 60.0 Series A Series B 2013 2014 2015 2016 2017 1H 2018 Median Round Size by Series Median 2-Year Series A to Series B Step-ups 0.8 3.2 2.3 0.0 1.0 2.0 3.0 4.0 Series A - Series B 2014-2016 2015-2017 2016-1H 2018 Roundsizesbythemost activeinvestorshave explodedin1H2018. Thishasbeenledbytop 15crossoverinvestors, whohaveshiftedfrom laterstage(SeriesC/D)to earlierstage(SeriesA/B) withtheexpectationof quickIPOs.For IPOs involvingtop15 crossoverinvestors,it tookamedian7.5months fromtheirlastprivate financingtogopublic. Higherpre-moneyIPO valuationsareleadingto largerstep-upsfrom SeriesA toB,allowing companiestoraisemore moneyandincrease valuations.SeriesA toB valuationstep-upshave soaredto3.2xin2017 and2.3xin1H2018. *Most ActiveBiopharma Investors by Indication defined as Top 42 venture and corporate investors calculated as new (first-time) investments into companies. Crossover investors defined as public-minded investors who opportunistically invest in private deals. Numbers denote median values. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data.
- 11. 4 6 5 5 3 7 11 8 7 3 4 7 2 2 4 5 2 Non-Invasive Monitoring Orthopedic Neuro Cardiovascular Imaging Ophthalmology 2016 2017 1H 2018 2016* 2017* 1H 2018 # of Investments 60 59 37 Total Series A Funding ($M) $284 $333 $232 Corporate Investments (%) 12% 21% 8% $120M $78M $86M $79M $45M Trends in Healthcare Investments and Exits Mid-Year 2018 11 Non-Invasive Monitoring Drives Device Series A U.S. Series A Device Investments, 2016 – 1H 2018 HC Insurers/Providers Medical Device Digital/Wellness/NIM $29M Biopharma *2016 &2017 numbers amended based on PitchBook financing updates. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data. Device Series A in 1H 2018 is slightly ahead of the 2017 pace, measured by deals and dollars. Hospital digitization technologies offered by non-invasive monitoring and imaging companies are driving 1H 2018 Series A activity. However, neuro- focused companies lagged. Since 2017, health insurers/providers and Chinese companies have led corporate investments in Series A device. J&J is the only traditional corporate to do a Series A deal since 2017, completing 3 early-stage investments. Series A Deals Series A by Indication Series A Corporate Investors: 2017 – 1H 2018
- 12. Trends in Healthcare Investments and Exits Mid-Year 2018 12 Traditional Venture Investors Support Device Most Active New Investors* in Device 2017 – 1H 2018 7 5 4 3 # OF DEALS New Enterprise Associates and Aperture Venture Partners join the most active new investor list. Early-stage groups like Keiretsu and FundRx are aggregating angel interest when approaching device investments. Corporate investor activity has declined. The most active corporate investors, J&J and Boston Scientific, are also major acquirers. *Most ActiveNew Investors in medical devicedefined as Top 21investors based on new investments in 2016–2017. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data. Corporate Investor
- 13. 5 4 5 3 1 4 2 1 1 4 3 4 2 2 1 1 2 4 1 1 Cardiovascular Neuro Orthopedic Surgical Metabolic Vascular Non-Invasive Monitoring ENT Aesthetics/ Dermatology Early Stage Late Stage Undesignated Trends in Healthcare Investments and Exits Mid-Year 2018 13 Device Investing Stays Consistent Most Active Device Investors by Indication*, 2017 – 1H 2018 $338M $182M $149M $219M $84M $100M $73M $76M # DEALS | $ MILLIONS $200M Orthopedic NIM Drug Delivery Trends: *Most ActiveDevice Investors defined as Top 35 venture and corporate investors calculated as new investments into companies in 2016 –2017. Early Stage defined as Series A & B; Late Stage defined as Series Cand later. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data. While active investor activity by indication is closely mirroring previous years, non-invasive monitoring (which has received a lot of early stage Series A interest) and drug delivery investment have not scaled as expected. Three neuro IPOs and a pair of uro/gyn M&A deals may spur additional interest in those areas. Cardiovascular Neuro Metabolic Surgical ENT Orthopedic Vascular Non-invasive Monitoring Aesthetics/ Dermatology Logos represent $25M+ financings
- 14. 1.7 2.2 0.6 1.7 0.8 1.1 1.4 1.2 1.2 2.0 1.4 0.7 0.0 1.0 2.0 3.0 Series A - Series B Series B - Series C Series C - Series D 2013-2015 2014-2016 2015-2017 2016-1H 2018 4.3 6.5 10.0 11.0 5.0 10.3 8.0 15.0 6.3 8.2 15.3 22.2 6.6 10.0 15.0 20.0 5.7 8.0 17.9 20.0 8.3 14.4 27.0 13.0 0.0 10.0 20.0 30.0 Series A Series B Series C Series D 2013 2014 2015 2016 2017 1H 2018 Median Round Size ($M) by Series 2013 – 1H 2018 Median 2-Year Series/Series Step-ups 2013 – 1H 2018 Trends in Healthcare Investments and Exits Mid-Year 2018 14 Device Round Sizes Increase as Later-Round Valuations Drop Median Round Size and Valuations (Pre/Post) by Series, 2013 – 1H 2018 Device round sizes have increased for Series A-C, up 2x in 1H 2018 over 2013. Series A to B valuation step-ups have recently reached as high as 2x. But Series C to D valuations are flat or down rounds, as later-stage investors may be bargain hunting with limited capital. This hampers returns for early-stage investors. Medical device companies funded between 2013and 1H2018. Source:PitchBook and SVB proprietary data as of 5/31/18
- 15. 26 20 8 42 22 9 16 7 4 R&D Tool Dx Test Dx Analytics 2016 2017 2018 2016* 2017* 1H 2018 # of Investments 54 73 27 Total Series A Funding ($M) $481 $548 $224 Corporate Investments (%) 21% 20% 17% Trends in Healthcare Investments and Exits Mid-Year 2018 15 Dx/Tools Series A Activity Declines from Record 2017 U.S. Series A Dx/Tools Investments, 2016 – 1H 2018 $678M $374M $201M Streamlined Dx Tests Neuro-Focused 3D Tissue Bioprinter Oncology-Focused NGS-Enabling Tools $5M+ Investments in 1H 2018 Dx/Tools Series A funding and deals decreased in 1H 2018 after a strong 2017. Dx Analytics companies had fewer deals but raised larger rounds in 1H 2018 with a median deal size of $18M. AI/ML dominated $10M+ Series A deals in 2017 (7/13), but only had one deal at $5M+ (PAIGE.AI) in 1H 2018. *2016 &2017 numbers amended based on PitchBook financing updates. Dx Tests are yes/no tests. Dx Analytics provide more information for diagnosis/treatment. R&D tools advance researchers’ capabilities. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data. Series A Deals Series A by Subsector 2016 – 1H 2018
- 16. 8 6 5 4 Corporate Investor Trends in Healthcare Investments and Exits Mid-Year 2018 16 New Tech Investors Join Most Active Dx/Tools List Most Active New Investors* in Dx/Tools, 2017 – 1H 2018 # OF DEALS The list of tech-focused investors active in Dx/Tools is impressive: Andreessen Horowitz and Alumni Ventures Group in 1H 2018 joined return investors AME Cloud Ventures, Data Collective, Google Ventures, Khosla Ventures and Tencent. We anticipate new tech-focused venture and corporate investors to become more active as opportunities to leverage software-based big data solutions emerge. *Most ActiveDx/Tools Investors calculated based onnew (first-time) investments into companies from 2017 to 1H2018. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data.
- 17. Dx Test Dx Analytics R&D Tool Trends in Healthcare Investments and Exits Mid-Year 2018 17 Dx/Tools Sector Dips in 1H 2018 but R&D Tools Surge Most Active Dx/Tools Investors* by Subsector, 2017 – 1H 2018 $1,889M $1,146M $1,443M 16 ($1,837M) 5 Dx/Tools saw $801M in investments by the most active investors in 1H 2018, compared to $2.8B invested in full-year 2017. Dx Analytics funding dropped to $322M with a focus on early-stage (seed and Series A/B). Dx Tests financing fell off the cliff from 2017, with just $52M in investments in 1H 2018; four big-money deals (including GRAIL and Guardant) pushed up investment totals in 2017. On the bright side, R&D Tools soared to 20 deals, with investments totaling $427M. That represents more than half of 1H 2018 Dx/Tools funding. 34% of R&D Tools investments were in tools that accelerate synthetic biology research, as detailed in the following slides. Logos represent $25M+ financings # DEALS | $ MILLIONS Dx Tests Dx Analytics R&D Tools *Most ActiveDx/Tools Investors calculated based onnew investments into companies from 2017 to 1H2018. Dx Tests are yes/no tests. Dx Analytics provide more information for diagnosis/treatment. R&D tools advance researchers’ capabilities. Financing data through 6/15/18. Source:PitchBook and SVB proprietary data. 2017 1H 2018 $52M 28 ($1,121M) 8 ($322M) 33 ($719M) 20 ($427M)
- 18. $0 $50 $100 $150 $200 $250 $300 $350 $400 $450 2015 2016 2017 2018 Design Editing Synthesis Engineering Trends in Healthcare Investments and Exits Mid-Year 2018 18 SVB Deep Dive: New Tools Accelerating Synthetic Biology in Life Sciences Investment by Synthetic Biology Subsector Computational design technologies provide data-backed suggestions for optimizing experiments and new molecules. CRISPR editing technologies simplify genemodifications. DNA/RNA synthesis technologies create DNA/RNA. Organism engineering technologies introduce DNA/RNA orediting tools into cells ororganisms. Financing data through 6/15/18. Source:PitchBook, press releases and SVB proprietary data. Computational Design Organism Engineering CRISPR Editing DNA/RNA Synthesis Large-scale synthetic biology is being simplified by innovations like CRISPR gene editing and machine learning. A new flood of therapeutics investment built around genome engineering is leveraging these groundbreaking technologies. This analysis focuses on companies making these tools that do not have a clinical or agricultural/industrial product pipeline. Buoyed by $100M+ investments in Zymergen, Twist Bioscience and Gingko Bioworks, sector financing has grown since 2015. While most investment has been in organism engineering, nucleic acid synthesis has dominated 1H 2018. DEAL SIZE | $ MILLIONS | 2015 – 1H 2018
- 19. Trends in Healthcare Investments and Exits Mid-Year 2018 19 SVB Deep Dive: Innovation in DNA/RNA Synthesis Companies with Venture-Backed Deals, Total Raised to Date HARDWARE ADVANCES BIOCHEMICAL ADVANCES >$50M High-Throughput,Silicon Platformthat Reducesthe Needed Volumesfor DNA SynthesisReactions Pairs High-Throughput SiliconPlatformwith Error Detectionand Annealing for CheckingDNA Quality Developinga Microfluidic, AutomatedSystemto Bring DNA Synthesisinto the Lab UtilizesReusable EnzymesfromDead Cellsto Produce RNA Template-FreeDNA Synthesisthrough ProprietaryEnzymes Template-FreeDNA Synthesisthrough ProprietaryEnzymes DNA/RNA synthesis technologies create DNA/RNA. Financing data through 6/15/18. Source:PitchBook, press releases and SVB proprietary data. TOTALRAISEDTODATE Semiconductor-based technology popularized by Twist Bioscience has now made high-throughput DNA/RNA synthesis possible. Evonetix builds upon this platform by integrating multiple reaction sites on the chip surface to error-check the synthesized DNA, and Synthomics aims to bring synthesis capabilities into labs by automating the entire process in a microfluidics-based device. Greenlight Biosciences, DNA Script and Molecular Assemblies utilize biocompatible enzymes to avoid error-prone synthesis steps. Integrating this enzymatic approach into recent hardware advances is ushering in a new era of synthetic biology research. $5–50M<$5M
- 20. 20 Healthcare Exits and IPOs: Biopharma IPOs Surge while M&A Slows Trends in Healthcare Investments and Exits Mid-Year 2018
- 21. Trends in Healthcare Investments and Exits Mid-Year 2018 21 Investors Find Blessing in 75 Biopharma Unicorns* VC-backed Biopharma $B+ M&A, Current Public Values, 2013 – 1H 2018 Public Unicorns by IPO Vintage: 46 Deals $B+ M&A Unicorns by Year: 19 Private/10 Public *Unicorn defined as venture-backed company since 2013that achieved an M&A with $B+ total deal value oris a public company (IPO since 2013) valued at $B+ as of 6/15/18. Source:PitchBook, press releases and SVB proprietary data. The hot biopharma sector has created a blessing of 75 unicorns between 2013 and 1H 2018. Half of private M&A unicorns were pre-clinical or Phase I (10/19), while all of the public M&A unicorns were Phase III (9) or commercial (1). Not all biopharma companies are build-to-sell. In fact, 61% of unicorns (46/75) have gone public and become stand-alone high-value companies. Of the 46 public unicorns, top 15 crossover investors participated in 31 of these deals prior to the IPO. 2013 2014 2015 2016 2017 2018 2013 2014 2015 2016 2017 Private M&A Public M&A
- 22. 33 67 42 28 31 30 12 14 22 20 14 5 2013 2014 2015 2016 2017 1H 2018 IPO M&A 23 8 10 5 4 55 29 25 19 16 Oncology Orphan/Rare Disease Neuro Anti-Infective Platform M&A IPO $- $5 $10 $15 $20 $25 $30 2013 2014 2015 2016 2017 1H 2018 M&A Upfront M&A Milestones Pre-Money IPO Trends in Healthcare Investments and Exits Mid-Year 2018 22 Biopharma M&A Slows as IPOs Heat Up VC-backed Biopharma Big Exits & IPOs, 2013 – 1H 2018 Source:PitchBook, press releases and SVB proprietary data. $17.7B $21.3B $26.9B $26.5B $18.7B $20.0B Exit Values by Year $ BILLIONS Top Exits by Indication 2013 – 1H 2018 As is typical in a hot IPO market,M&A activityslowed significantlyin 1H 2018. By mid-year,30 biopharma IPOs had priced– comparedto 31 for all of 2017. The biopharma IPO queueis substantial,and 2H 2018 activity will likely push the full year total to between40 and 45 – far surpassing our early 2018 predictionof 28 to 32. Thoughthe numberof deals declined,total M&A deal valuein 1H 2018 alreadyhas blownpast the total for full-year2017. However,hugemilestones drive thesedeals: 3 involvepotentialearn-outsof $900M or higher. Oncologyled the 1H 2018 M&A/IPO exit pack (10), followedby platform(7), orphan/rare(4) and aesthetics/dermatology(4). Aesthetics/dermatologyis a surprise becauseof its relativelysmall investmentlevels. # of Exits by Year
- 23. Trends in Healthcare Investments and Exits Mid-Year 2018 23 Smaller Early-Stage Deals Dominate Biopharma M&A VC-backed Biopharma Big Exit M&A by Stage* 2013 – 1H 2018 *Stage defined as last completed clinical trial in most advanced asset. Source:PitchBook, press releases and SVB proprietary data. 1 5 7 2 5 1 2 3 4 8 2 3 4 4 10 9 5 2 1 1 1 3 1 1 1 2013 2014 2015 2016 2017 1H 2018 While overall M&A activity is down, 1H 2018 saw 4 early-stage exits – which signals that pre-clinical/Phase I deals may hit the typical annual total of 7 to 11 exits. The 1H 2018 median milestone earn- out of $900M is nearly double the median from 2015 to 2017. Smaller early-stage deals, with median investment of $17M, are providing quick times to exit of 3.1 years. They are also yielding a 7x median upfront multiple on invested capital, making the deals attractive to investors. To exit at an early stage, companies typically need to show a minimum 3x to investors. However, early-stage investment rounds are shifting to $50M and higher, and with the median M&A upfront value at $123M, a 3x return is out of reach. Instead, these companies are heading to the public markets with pre-money IPO valuations far exceeding the private upfront M&A value, providing a hefty step-up from the last private round and generating large IPO proceeds to continue asset development. Median Upfront($M) 213 225 200 200 171 123 Median Total Deal($M) 457 413 570 600 461 1040 Median Years to Exit 5.6 4.0 4.2 5.9 3.5 3.1 Phase III Phase II Phase I Pre-Clinical Commercial $7.0B $8.0B $16.6B $21.2B $8.9B $9.9B # of Big Exits
- 24. $182 $129 $193 $140 $294 $327 0 50 100 150 200 250 300 350 400 450 500 2013 2014 2015 2016 2017 2018 $71 $61 $71 $53 $85 $100 0 20 40 60 80 100 120 140 2013 2014 2015 2016 2017 2018 IPO Pre-Money Value* $ MILLIONS Trends in Healthcare Investments and Exits Mid-Year 2018 24 Biopharma Pre-Money Values Drive Hot IPO Scene VC-backed IPOs by Pre-Money Valuation and Dollars Raised, 2013 – 1H 2018 Source:PitchBook, press releases and SVB proprietary data. *Pre-money IPO valuation divided by venture capital invested. Private valuations sourced through PitchBook. 2013 2014 2015 2016 2017 1H 2018 IPOs Raised $100M+ 8 12 13 1 12 17 % of IPOs Raised $100M+ 24% 18% 31% 4% 39% 57% IPO Proceeds $ MILLIONS 75th Quartile 25th Quartile IPO Median Pre-Money IPO Median Dollars Raised Half of H1 2018 IPOs raised at least $100M, spurred on by pre-money IPO valuations hitting cycle-highs. The median step-up from last round private money to pre-money IPO was 1.2x. About half of the IPOs were pre-clinical/Phase I (14/30). Top 15 crossover investors remain major players, as an impressive 21 of 30 IPOs included at least one top 15 crossover investor in the private syndicate. These IPOs had a higher median pre-money value ($341M) and better step-up from last round private money (1.3x). Historically, these IPOs perform better in the public markets. 1H 1H
- 25. 21 12 11 5 8 1 4 4 6 3 Cardiovascular Vascular Access Surgical Neuro Ophthalmology M&A IPO $- $1 $2 $3 $4 $5 $6 $7 $8 2013 2014 2015 2016 2017 1H 2018 M&A Upfront M&A Milestones Pre-Money IPO 2 10 11 3 3 3 12 18 19 13 14 6 2013 2014 2015 2016 2017 1H 2018 IPO M&A Trends in Healthcare Investments and Exits Mid-Year 2018 25 Device M&A Activity Stable but IPO Window Cracks Open VC-backed Device Big Exits & IPOs, 2013 – 2017 Exit Values by Year $ BILLIONS Top Exits by Indication 2013 – 1H 2018 Source:PitchBook, press releases and SVB proprietary data. $2.8B $6.4B $7.6B $4.9B $4.9B $2.6B The slow start to the year is typical for device, and activity should increase in 2H 2018. J&J and Boston Scientific continue acquiring venture-backed companies, but Medtronic and Abbott remain quiet after huge public acquisitions in 2015 and 2017. Further consolidation among large device companies could hurt M&A exits. The three device IPOs in 1H 2018 equal full-year 2017 activity. Neuro-focused IPOs by Inspire Medical Systems, electroCore and Neuronetics have performed well and could lead to a few more IPOs by revenue-generating device companies in 2H 2018. # of Exits by Year
- 26. 1 1 4 2 3 1 3 1 5 4 3 8 15 10 7 8 5 0 2 4 6 8 10 12 14 16 18 20 2013 2014 2015 2016 2017 1H 2018 Trends in Healthcare Investments and Exits Mid-Year 2018 26 Device M&A Upfront Deal Values Dip VC-backed Device Big Exit M&A by Stage 2013 – 1H 2018 By indication, 1H 2018 M&A exits were cardiovascular (2), uro/gyn (2), orthopedic (1) and non-invasive monitoring (1). Cardiovascular has remained strong for the last 5 years. Building on a two-year trend, 4 of 6 device deals had milestone earn-outs. The sole PMA/De Novo acquisition was for a non- approved device and the four 510(k) acquisitions had FDA approvals. Median Upfront($M) 127 180 125 120 131 113 Median Total Deal($M) 175 185 141 380 283 263 Median Years to Exit 6.6 6.9 7.0 8.1 7.7 13.4 U.S. Commercial CE Mark Only Non-approved $2.3B $4.3B $3.7B $4.4B $4.7B $1.6B Source:PitchBook, press releases and SVB proprietary data. # of Big Exits
- 27. 510(k) Big Exits (29 Deals) 2015 – 1H 2018 2015 – 2016 (18 Deals) 2017 – 1H 2018 (11 Deals) Median Upfront Value ($M) $105M $125M Median Upfront Deal Multiple 2.2X 3.5X Median Total Deal Value ($M) $110M $250M Median Total Deal Multiple 2.6X 5.7X Trends in Healthcare Investments and Exits Mid-Year 2018 27 PMA/De Novo Deals Exit Pre-FDA Approval VC-backed Device M&A by Pathway, 2015 – 1H 2018 2015 – 1H 2018 Stage at Exit Median Invested ($M) Median Upfront ($M) Median Upfront Multiple Median Total Deal ($M) Median Total Deal Multiple Median Time to Exit (Years) 510(k)M&As 29 Exits $46 $110 3.1x $135 3.6x 9.1 PMA/DeNovo 510(k)M&As 22 Exits $45 $225 4.0x $353 6.8x 5.5 BiopharmaM&As 60 Exits $37 $200 4.4x $578 12.5x 4.2 1 2 9 11 27 32 28 1 ≥ Phase IDevelopment StageCE Mark OnlyFDA-Approved < Phase I Device M&A continues the trend of early-stage PMA/De Novo exits and commercial-stage 510(k) exits. The median upfront deal value of 510(k) companies has increased and the total deal value has more than doubled from 2015 – 2016 to 2017 – 1H 2018. This has resulted in higher deal value multiples, with upfront multiples increasing from 2.2x to 3.5x. Source:PitchBook, press releases and SVB proprietary data.
- 28. 2 7 5 2 4 4 11 5 4 5 0-1.0x 1.1-2.0x 2.1-4.0x 4.1x-7.0x 7.1-10.0x >10.1x IPO M&A Despite experiencing a large 1H 2018 bump in M&A activity and with immense private capital invested, Dx/Tools M&A deals were smaller with long times to exit. Many high-value companies remain private. Of 28 companies with $150M post-money valuations since 2015, only 3 have exited: Assurex, Astute and Natera. Tech companies continue to expand into healthcare through Dx/Tools investments: Google, Fitbit, Microsoft and Nikon were new corporate investors in 1H 2018 deals. Looking ahead, tech acquisitions of Dx Analytics companies are likely in the next two years as tech companies expand their healthcare footprint and move from investment to acquisition. 4 6 5 1 3 10 8 5 7 2013 2014 2015 2016 2017 1H 2018 IPO M&A $- $0.5 $1.0 $1.5 $2.0 $2.5 $3.0 2013 2014 2015 2016 2017 1H 2018 MeanYearstoIPO 10.9 6.5 7.7 N/A N/A 4.1 Mean Years to M&A 9.1 10.3 7.4 6.4 2.6 4.7 Trends in Healthcare Investments and Exits Mid-Year 2018 28 Dx/Tools M&A Is Up but Values Decline VC-backed Dx/Tools Exits & IPOs, 2013 – 1H 2018 IPO/Exit Multiples* 2013 – 1H 2018 $1.0B $1.4B $1.5B No Exits Source:PitchBook, press releases and SVB proprietary data. *Exit multiple calculated as upfront deal value divided by private invested capital. Dx Tests are yes/no tests. Dx Analytics provide more information for diagnosis/treatment. R&D Tools advance researchers’ capabilities. MedianUpfront($M) 350 133 164 225 N/A 105 Median Total Deal ($M) 450 239 164 325 N/A 130 Median Years to Exit 8.2 6.0 3.6 8.5 N/A 8.1 $1.6B Exit Values by Year $ BILLIONS $2.8B # of Exits by Year R&D Tools Dx Analytics Dx Tests
- 29. Second Half of 2018 Outlook Trends in Healthcare Investments and Exits Mid-Year 2018 29 • Wepredictfull-year2018U.S. healthcareventurefundraisingwillreach$9 billion,closelymatchingtherecord $9.1billionsetin 2017. • Whilethepaceofbiopharmainvestmentsmay slowin 2H2018,continuinglargeroundsizes likelywillpropel theannualinvestmenttotaltoa recordhigh. • BiopharmaM&Ais likelytoreachbetween11 and 13 deals fortheyear. Mostcompanieswillpushtothepublic marketstoseekhigher-valueIPOs. Weexpectbetween40and 45IPOs for2018, absentunexpectedmarket fluctuations. • SeriesCand D dealswilldriveinvestmentin thedevicesector;however,SeriesD valuationresetscoulddilute early-stageinvestors. • DeviceM&Aactivity shouldpickup,withquick PMA/DeNovoexitsand improvingmultiplesfor510(k) exits. WeexpectanotherthreeIPOs in 2H2018,whichwouldbedoublethe2017number. • Dx/Toolsinvestmentwillfallshortofrecordyear 2017.Investmentin 2H2018willcontinuetofocusonR&D Toolscompanies. • Thefieldofsyntheticbiologywillcontinuetogrowas pioneeringcompaniesmakehardwareand biochemical advancesin DNA/RNAsynthesis. • HighlyvaluedR&DToolsand liquid biopsycompaniesmay testthepublicmarketsin theU.S. orHongKong, and weexpectadditional DxTests M&Aactivity.
- 30. Trends in Healthcare Investments and Exits Mid-Year 2018 30 Glossary Big Exits Big Exits defined as a private, venture-backed merger and acquisition in which the upfront payment is $75 million or more for biopharma deals and $50 million or more for device and Dx/Tools deals. Initial Public Offering IPO defined as a venture-backed company raising IPO proceeds of $25 million or more. Deal Descriptions Structured Deal defined as a pay-for-performance acquisition where some of the deal value is paid upfront when the deal closes, but also contains additional value based on milestones that must be achieved. All-in Deal defined as an acquisition where the full deal value is paid on deal close. Upfront Payments defined as initial proceeds from an acquisition paid upon the close of a structured deal; it does not include milestones. Milestones to be Earned defined as proceeds from an acquisition that are paid once predetermined milestones are met. Total Deal Value defined as the full value of the acquisition, including any milestones to be earned. Time to Exit defined as the time from the close of a company’s first institutional round of financing to the exit. Corporate Investor Corporate Investor defined as both corporate venture and parent company investment into venture-backed companies Regulatory Non-approved defined as a device company that has no regulatory approval for its product. CE Mark Only defined as a device company that has CE Mark approval but has not received FDA approval. CE Mark is a European Union designation that is typically less difficult to obtain than FDA approval, and the approval process often has a faster timeline. U.S. Commercial defined as a device company that has received FDA approval of its product and usually is in commercial stage. Series A Series A defined as all first-round institutional or corporate venture investment, and all first-round investments equal to or greater than $2M regardless of investor. Indication Definitions Neurology (neuro) defined as CNS, pain and psychology companies. Non-Invasive Monitoring defined as medical data collection through sensors and other technology. Dx Tests defined as proprietary Yes/No diagnostic tests. Dx Analytics defined as actionable data analytics to help determine/direct treatment. R&D Tools defined as research equipment/services for biopharma and academia. Top 15 Crossover Investor Top 15 Crossover Investor defined as public-minded investor who strategically invests in private companies. Top 15 list includes: Cormorant Asset Management, Deerfield Management, EcoR1 Capital, Fidelity Investments, Foresite Capital Management, Jennison Associates, Partner Fund Management, Perceptive Advisors, RA Capital Management, Redmile Group, Rock Springs Capital, Sectoral Asset Management, Viking Global Investors, Wellington Management and Woodford Investment Management.
- 31. JonathanNorris ManagingDirector SiliconValleyBank [email protected] @jonnysvb RitishPatnaik HealthcareConsultant [email protected] AndrewOlson SeniorManager SVBStrategicAdvisory [email protected] BillSideris SeniorAssociate SVBStrategicAdvisory [email protected] About the Authors Trends in Healthcare Investments and Exits Mid-Year 2018 31 AsaManagingDirector,JonathanNorrisspearheadsstrategicrelationshipswithmanyhealthcareventurecapitalfirms.In addition,hehelpsSVBCapitalthroughsourcingandadvisingonlimitedpartnershipallocationsanddirectinvestments. Jonathanspeaksatmajorinvestorandindustryconferencesandauthorswidelycitedanalysesofhealthcareventurecapital trends.Hehas17+yearsofbankingexperienceworkingwithhealthcarecompaniesandventurecapitalfirms.Jonathanearned aB.S.inBusinessAdministration fromtheUniversityofCalifornia,Riverside,andaJ.D.fromSantaClaraUniversity. AsaHealthcareConsultant,RitishPatnaikhelpeddevelopSVB’sDx/ToolsandSyntheticBiologyclassificationschemes.Healso helpedanalyzethedatasets,generatenewslidesandputtogethertakeaways forinvestmenttrendspresentedinthisreport. Ritish ispursuinga Ph.D. inBioengineeringandM.S. inManagementScienceandEngineeringat StanfordUniversitywherehe is using bioinformatics and magnetics to create a liver cancer liquid biopsy test. He is a co-founder in Luso Labs, a startup that bringsaffordablecervicalcancerscreeningworldwide.Ritish earnedaB.S.inBiomedicalEngineeringatColumbiaUniversity. AndrewOlson is part of SVB’s strategicadvisory groupwherehe partners with both early-stageand larger biotech companiesto helpthem navigatethe strategicinvestingand M&A landscape. Beforejoining SVB, Andrewwas a managementconsultantat ZS Associates,wherehe focusedon forecasting,pipeline strategyand market researchfor pharmaceuticaland biotechcompanies.He holds a B.A. in Chemistryfrom Carleton Collegein Northfield,Minnesota,and a Ph.D. in Chemistryfromthe Universityof California, Berkeley. As part of SVB’s strategic advisorygroup,Bill Sideris helpsclientsrefine and executetheir strategicinvestingand M&A strategyas theycreatethe next generationof medicaltechnologies. Prior to joining SVB,Bill worked as an R&D engineerat AbbottLaboratoriesfocusedon medicaloptics.Bill also co- foundedCardian Inc.,a private medicaldevicecompanydevelopinga clinicalstage cardiovascular technologyfor stroke prevention.Bill completedhis PDEng at the TechnicalUniversityof Delft in BioproductDesignand holds both a B.S. and M.S. in BiomedicalEngineeringfrom the Universityof Houston.
- 32. About Silicon Valley Bank For 35 years, Silicon Valley Bank has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators. This material including, without limitation, to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable but which have not been independently verified by us, and for this reason, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment or to engage in any other transaction. SVB Securities is a non-bank affiliate of Silicon Valley Bank. SVB Securities does not provide investment, tax, or legal advice. Please consult your investment, tax, or legal advisors for such guidance. SVB Securities is a member of FINRA and SIPC. Products and services offered by SVB Securities are not insured by the FDIC or any other federal government agency, are not deposits of or guaranteed by a Bank and may lose value. Silicon Valley Bank is registered in England and Wales at Alphabeta, 14-18 Finsbury Square, London EC2A 1BR, UK under No. FC029579. Silicon Valley Bank is authorised and regulated by the California Department of Business Oversight and the United States Federal Reserve Bank; authorised by the Prudential Regulation Authority with number 577295; and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. Silicon Valley Bank is not authorized to undertake regulated activity in Canada and provides banking services from its regulated entities in the United States and the United Kingdom. © 2018 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB). SVB Securities 0718-0002KHEXP073119